Tumors Clinical Trial
Official title:
A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
This is an open-label Phase 1b/2 trial of lenvatinib (E7080) plus pembrolizumab in participants with selected solid tumors. Phase 1b will determine and confirm the maximum tolerated dose (MTD) for lenvatinib in combination with 200 milligrams (mg) (intravenous [IV], every 3 weeks [Q3W]) pembrolizumab in participants with selected solid tumors (i.e. non-small cell lung cancer, renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, melanoma or leiomyosarcoma). Phase 2 (Expansion) will evaluate the safety and efficacy of the combination in 7 cohorts at the MTD from Phase 1b (lenvatinib 20 mg/day orally + pembrolizumab 200 mg Q3W, IV).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Suspended |
NCT01562626 -
Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00435669 -
A Phase I Study to Determine Absorption, Distribution, Metabolism, and Elimination of a Single Radiolabeled Dose of Brivanib (BMS-582664)
|
Phase 1 | |
| Completed |
NCT00395434 -
Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00372437 -
A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine
|
Phase 1/Phase 2 | |
| Completed |
NCT00400023 -
A Phase 1, Open-Label, Randomized, Cross-Over, Pharmacokinetic Study Evaluating the Effect of S-1 on Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00375245 -
Rapamycin With Grapefruit Juice for Advanced Malignancies
|
Phase 1 | |
| Completed |
NCT00410696 -
Pegfilgrastim Versus Filgrastim After High-dose Chemotherapy
|
Phase 2 | |
| Recruiting |
NCT00553033 -
Laparoscopic Liver Resection
|
N/A | |
| Completed |
NCT00248404 -
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
|
Phase 1/Phase 2 | |
| Completed |
NCT00207103 -
MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors
|
Phase 1 | |
| Completed |
NCT00222443 -
Pilot Study Combining Temozolomide, Oncovin, Camptosar and Oral Antibiotic in Children and Adolescents With Recurrent Malignancy
|
Phase 1 | |
| Terminated |
NCT03251924 -
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05103969 -
Cohort of Tumors With POLE/D1 Mutation
|
||
| Completed |
NCT00446446 -
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
|
Phase 2 | |
| Completed |
NCT02275910 -
Phase 1 Study of E7090 in Subjects With Solid Tumor
|
Phase 1 | |
| Terminated |
NCT02271516 -
to evaluate188Re-BMEDA-liposome in Patient With Primary Solid Tumor in Advanced or Metastatic Stage
|
Phase 1 | |
| Completed |
NCT01448759 -
Evaluation of Plasma Alcohol Concentration in Patients Receiving Paclitaxel or Docetaxel
|
N/A | |
| Terminated |
NCT01081808 -
Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and Sargramostim (GM-CSF) in Treating Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00398814 -
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
|
Phase 1 | |
| Completed |
NCT00389480 -
Study of AR-67 (Formerly DB-67) in Adult Patients With Refractory or Metastatic Solid Malignancies
|
Phase 1 |